Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can new scans predict chemo success in Triple-Negative breast cancer?

NCT ID NCT02744053

Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether two advanced imaging techniques—DCE-MRI and molecular breast imaging (MBI)—can accurately assess how triple-negative breast cancer tumors respond to chemotherapy. About 96 patients will undergo these scans before, during, and after treatment. The goal is to see if these imaging methods can predict which patients are responding well, potentially helping doctors tailor treatment earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Technetium Tc-99m Sestamibi (imaging tracer)
What this could lead to
If successful, this could help doctors predict which triple-negative breast cancer patients are responding to chemotherapy, potentially guiding more personalized treatment.
What could go wrong
This is a very early (phase 1) imaging study with only 96 participants, so results may not apply broadly. It focuses on measuring response, not on improving outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

96 people

The number who actually took part.

Started

Nov 2016

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient has proven TNBC, defined by standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (\< 10% tumor staining) and negative for human epidermal growth factor 2 (HER2) (immunohistochemistry \[IHC\] score \< 3, gene copy number not amplified) * TNBC patients who are previously untreated and enrolled in the prospective Institutional Review Board (IRB) approved clinical trial: 2014-0185 * Patients who are able to understand and give consent to participating in the study Exclusion Criteria: * Is pregnant (confirmed by the patient as imaging clinic standard of care) or nursing mother * Has lesions involving chest wall * Has known allergy to Tc99m sestamibi * Has known contraindications to MRI * Has contraindication to MRI contrast

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Estrogen receptor negative are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

estrogen-receptor negative breast cancer Her2-receptor negative breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Estrogen receptor negative HER2/neu negative Progesterone receptor negative Triple-negative breast carcinoma

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • MD Anderson League City

    Nassau Bay, Texas, 77058, United States

  • MD Anderson in Katy

    Houston, Texas, 77094, United States

  • MD Anderson in Sugar Land

    Sugar Land, Texas, 77478, United States

  • MD Anderson in The Woodlands

    The Woodlands, Texas, 77384, United States

  • Memorial Hermann Memorial City Medical Center

    Houston, Texas, 77024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.